The Role of Denosumab and Bisphosphonate in Osteogenesis Imperfecta: A Literature Review
Open Access
- 4 April 2024
- journal article
- review article
- Published by Salud, Ciencia y Tecnologia in Salud, Ciencia y Tecnología
- Vol. 4, 894
Abstract
Osteogenesis Imperfecta (OI) is a rare genetic disorder characterized by brittle bones and susceptibility to fractures. Management of OI focuses on minimizing fractures and improving bone strength. Denosumab and bisphosphonates have emerged as potential therapeutic agents in OI management due to their ability to modulate bone turnover. This literature review aims to explore the role of denosumab and bisphosphonates in the treatment of OI, highlighting their mechanisms of action, efficacy, and safety profiles. A comprehensive search was conducted across various databases, to identify relevant studies investigating the use of denosumab and bisphosphonates in OI management. The review discusses the molecular pathways underlying the pathogenesis of OI and how denosumab and bisphosphonates intervene in these pathways to improve bone quality. Furthermore, the review summarizes the findings from clinical trials and observational studies evaluating the effectiveness of denosumab and bisphosphonates in reducing fracture rates, improving bone mineral density, parathyroid hormone changes, calcium and phosphate quantity, and also enhancing functional outcomes in patients with OI. Additionally, considerations regarding optimal dosing, timing of initiation, and potential adverse effects of denosumab and bisphosphonates in individuals with OI are discussed. The synthesis of existing evidence underscores the promising role of denosumab and bisphosphonates as adjunctive therapies in the management of OI, although further research is warranted to elucidate their long-term efficacy and safety profiles in this patient populationKeywords
This publication has 38 references indexed in Scilit:
- Bisphosphonates for osteoporosis in people with cystic fibrosisCochrane Database of Systematic Reviews, 2023
- Denosumab in the Treatment of Osteoporosis: 10 Years Later: A Narrative ReviewAdvances in Therapy, 2021
- A Bisphosphonate With a Low Hydroxyapatite Binding Affinity Prevents Bone Loss in Mice After Ovariectomy and Reverses Rapidly With Treatment CessationJBMR Plus, 2021
- Nosology and classification of genetic skeletal disorders: 2019 revisionAmerican Journal of Medical Genetics Part A, 2019
- Alterations in non-type I collagen biomarkers in osteogenesis imperfectaBone, 2019
- Long-Term Bisphosphonate Therapy in Osteogenesis ImperfectaCurrent Osteoporosis Reports, 2017
- Bisphosphonate therapy for osteogenesis imperfectaCochrane Database of Systematic Reviews, 2016
- Scoliosis in osteogenesis imperfecta caused by COL1A1/COL1A2 mutations — genotype–phenotype correlations and effect of bisphosphonate treatmentBone, 2016
- Intravenous Bisphosphonate Therapy of Young Children With Osteogenesis Imperfecta: Skeletal Findings During Follow Up Throughout the Growing YearsJournal of Bone and Mineral Research, 2015
- Denosumab and bisphosphonates: Different mechanisms of action and effectsBone, 2011